噻唑烷二酮类药物使用与年龄相关性黄斑变性治疗试验比较中的视网膜积液
该研究为年龄相关性黄斑变性治疗试验比较(CATT)的二次分析,评估使用噻唑烷二酮类药物的糖尿病患者接受贝伐珠单抗或雷珠单抗治疗新生血管性年龄相关性黄斑变性(nAMD)后,视网膜形态学结局与视力的关联。结果显示,使用噻唑烷二酮类药物者基线视力更差,第2年视网膜内积液比例更高,第1年和第2年视网膜下厚度及视网膜下组织复合体厚度较基线下降更多。
要点
- 使用噻唑烷二酮类药物的糖尿病患者基线平均视力评分较未使用者低6.2个字母(p=0.02)。
- 第2年视网膜内积液比例在使用者中为75%,未使用者为50%(校正OR 2.8;p=0.04)。
- 使用者第1年视网膜下组织复合体厚度较基线下降更多(差值-75.1微米;p=0.02)。
核心结论
- 在探索性分析中,使用噻唑烷二酮类药物的糖尿病患者接受贝伐珠单抗或雷珠单抗治疗nAMD后,基线平均视力更差、视网膜下和视网膜下组织复合体厚度较基线下降更多、视网膜内积液比例更高。
研究设计与样本
- 年龄相关性黄斑变性治疗试验比较(CATT)的二次分析。
- 参与者基线时自我报告糖尿病状态和噻唑烷二酮类药物使用情况。
- 基线及2年随访期间评估视力、视网膜内、视网膜下和视网膜色素上皮下积液以及视网膜各层中心凹厚度。
- 使用噻唑烷二酮类药物组(n=30)与未使用组比较,在多变量回归模型中按黄斑新生血管病变类型校正。
主要发现
- 使用噻唑烷二酮类药物组(n=30)基线校正平均视力评分较未使用组低6.2个字母(p=0.02)。
- 第2年视网膜内积液比例使用组为75%,未使用组为50%(校正OR 2.8;p=0.04)。
- 第1年视网膜下组织复合体厚度较基线平均下降值使用组比未使用组多75.1微米(差值-75.1微米;p=0.02)。
- 第1年视网膜下厚度较基线平均下降值使用组比未使用组多41.9微米(差值-41.9微米;p=0.001),第2年多43.3微米(差值-43.3微米;p=0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thiazolidinediones, commonly used antidiabetic medications, have been associated with an increased risk of development of diabetic macular oedema and increased vascular endothelial cell permeability. Macular neovascularisation in age-related macular degeneration (AMD) and associated fluid leakage may be influenced by thiazolidinediones. This study aims to determine the association between thiazolidinedione usage and retinal morphological outcomes or visual acuity (VA) in patients treated with bevacizumab or ranibizumab for neovascular AMD (nAMD). METHODS: Secondary analysis of data from the Comparison of Age-related Macular Degeneration Treatments Trials. Participant self-reported diabetes status and thiazolidinedione usage at baseline. VA, intraretinal, subretinal and subretinal pigment epithelium fluid, and foveal thickness of retinal layers were evaluated at baseline and during 2-year follow-up. Comparisons of outcomes between thiazolidinedione usage groups were adjusted by macular neovascularisation lesion type in multivariable regression models. RESULTS: Patients taking thiazolidinedione (n=30) had lower adjusted mean VA score at baseline (difference -6.2 letters; p=0.02), greater proportion with intraretinal fluid (IRF) at year 2 (75% vs 50%, adjusted OR 2.8; p=0.04), greater mean decrease in subretinal tissue complex thickness from baseline at year 1 (difference -75.1 um; p=0.02) and greater mean decrease in subretinal thickness at year 1 (difference -41.9 um; p=0.001) and year 2 (difference -43.3 um; p=0.001). CONCLUSIONS: In this exploratory analysis, patients with diabetes taking thiazolidinediones and treated with bevacizumab or ranibizumab for nAMD had worse baseline mean VA, greater reductions in subretinal and subretinal tissue complex thickness from baseline, and greater proportions with IRF comparing to patients not taking thiazolidinediones. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov NCT00593450.
引用
- Core JQ, Hua P, Daniel E, et al. Thiazolidinedione use and retinal fluid in the comparison of age-related macular degeneration treatments trials. Br J Ophthalmol. 2022. PMID: 35428655. doi:10.1136/bjophthalmol-2021-320665
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。